Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PHARM.AS
- Price
- 0.91
- Stock movement up
- +0.00 (0.33%)
- Company name
- Pharming Group NV
- Exchange
- (AS ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 617.98M
- Ent værdi
- 757.04M
- Pris/omsætning
- 2.16
- Pris/bog
- 2.74
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- 17.93%
- 3 års afkast
- 6.23%
- 5 års afkast
- -4.40%
- 10 års afkast
- 11.65%
Senest opdateret: 2025-06-22
UDBYTTE
PHARM.AS betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | 1370.24 |
| Pris til FCF | - |
| Pris til EBITDA | 65.97 |
| EV i forhold til EBITDA | 80.82 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 2.16 |
| Pris til egenkapital | 2.74 |
| EV i forhold til salg | 2.65 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 678.35M |
| EPS (TTM) | -0.03 |
| FCF pr. aktie (TTM) | -0.00 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 285.75M |
| Bruttofortjeneste (TTM) | 255.44M |
| Driftsindkomst (TTM) | -14.26M |
| Nettoindkomst (TTM) | -17.82M |
| EPS (TTM) | -0.03 |
| EPS (1 år frem) | -0.01 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 89.39% |
| Driftsmargin (TTM) | -4.99% |
| Fortjenstmargin (TTM) | -6.24% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 60.66M |
| Nettotilgodehavender | 48.20M |
| Omsætningsaktiver i alt | 282.19M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 30.67M |
| Sum aktiver | 425.51M |
| Kreditor | 72.64M |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 79.84M |
| Sum gæld | 199.72M |
| Aktionærernes egenkapital | 225.79M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 451.00K |
| Investeringsudgifter (TTM) | 991.00K |
| Fri pengestrøm (TTM) | -540.00K |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -7.89% |
| Afkast af aktiver | -4.19% |
| Afkast af investeret kapital | -5.61% |
| Kontant afkast af investeret kapital | -0.17% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.91 |
| Daglig høj | 0.93 |
| Daglig lav | 0.91 |
| Daglig volumen | 5.84M |
| Højeste gennem alle tider | 306.70 |
| 1 års analytiker estimat | 1.70 |
| Beta | 0.81 |
| EPS (TTM) | -0.03 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 31 Jul 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| PHARM.AS | S&P500 | |
| Nuværende prisfald fra top notering | -99.70% | -3.04% |
| Højeste prisfald | -99.98% | -56.47% |
| Højeste efterår dato | 23 Apr 2013 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -93.26% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 289 days | 12 days |
| Maks. tid til nyt højdepunkt | 6456 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
617.98M
Markedsværdi kategori
Small-cap
Beskrivelse
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Personale
382
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Netherlands
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Results enable clinical genetic testing labs to appropriat...
24. juni 2025
As the European markets experience a boost with the pan-European STOXX Europe 600 Index rising 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are ...
13. juni 2025
Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) ...
11. juni 2025
Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor confere...
28. maj 2025
As European markets show resilience with the STOXX Europe 600 Index rising for a fourth consecutive week, investors are increasingly optimistic about easing trade tensions between China and the U.S. I...
14. maj 2025
The European market has seen a positive trend with the STOXX Europe 600 Index rising for the fourth consecutive week, buoyed by hopes of easing trade tensions between China and the U.S. In this enviro...
12. maj 2025
Pharming Group ( AMS:PHARM ) First Quarter 2025 Results Key Financial Results Revenue: US$79.1m (up 42% from 1Q 2024...
10. maj 2025
Pharming Group (PHGUF) reports a 42% revenue increase, driven by Ruconest and Joenja sales, while navigating acquisition costs and potential tariff challenges.
9. maj 2025
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, ref...
8. maj 2025
Pharming Group (PHGUF) is set to release its Q1 2025 earnings on May 8, 2025. The consensus estimate for Q1 2025 revenue is $67.74 million, and the earnings are expected to come in at -$0.03 per shar...
7. maj 2025
Næste side